Challenges and Opportunities in Drug Delivery Research

Abstract submission deadline

31 December 2024

Manuscript submission deadline

31 March 2025

Viewed by

2155

Topic Information

Dear Colleagues,

The topic "Challenges and Opportunities in Drug Delivery Research" encompasses innovative drug delivery and release science research with significant implications in medical fields such as cancer therapy, neurology, and cardiovascular medicine. This pioneering research aims to transform treatment methods by developing advanced drug delivery systems that improve precision, reduce side effects, and enhance patient outcomes. The scope extends to gene therapies, personalized medicine, and novel approaches addressing complex health challenges, potentially reshaping healthcare by providing tailored and effective solutions for various diseases and conditions.

Key focus areas involve a mechanistic comprehension of drug delivery systems based on biological and physicochemical principles and mathematical modeling, predictive analytics, drug delivery systems, and cellular interactions tailored for particular therapeutic objectives.

Potential topics of interest for discussion cover various drug delivery technologies, nanomedicine, different entry pathways into the human body, technology evaluations, drug delivery strategies, precise delivery and targeting at various levels and disease indications, and preclinical and clinical findings data related to drug delivery systems. Additionally, in-depth discussions could be extended to detailed explorations of the methods involved in delivering and releasing genes, vaccines, and antibodies.

Prof. Dr. Lenuta Profire
Dr. Ioana Mirela Vasincu
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Current Issues in Molecular Biology cimb	2.8	2.9	1999	13.5 Days	CHF 2200	Submit
Molecules molecules	4.2	7.4	1996	14.6 Days	CHF 2700	Submit
Pharmaceuticals pharmaceuticals	4.3	6.1	2004	14.6 Days	CHF 2900	Submit
Pharmaceutics pharmaceutics	4.9	7.9	2009	14.2 Days	CHF 2900	Submit
Scientia Pharmaceutica scipharm	2.3	4.6	1930	22.7 Days	CHF 1000	Submit

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

1. Immediately share your ideas ahead of publication and establish your research priority;
2. Protect your idea from being stolen with this time-stamped preprint article;
3. Enhance the exposure and impact of your research;
4. Receive feedback from your peers in advance;
5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (3 papers)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All CIMB Molecules Pharmaceuticals Pharmaceutics Sci. Pharm.

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

15 pages, 7838 KiB  

Open AccessArticle

Enhanced Cellular Doxorubicin Uptake via Delayed Exposure Following Nanosecond Pulsed Electric Field Treatment: An In Vitro Study

by Rongwei Ma, Yubo Wang, Zhihao Wang, Shengyong Yin, Zhen Liu and Keping Yan

Pharmaceutics 2024, 16(7), 851; https://doi.org/10.3390/pharmaceutics16070851 - 24 Jun 2024

Viewed by 263

Abstract

The combination of nanosecond Pulsed Electric Field (nsPEF) with pharmaceuticals is a pioneering therapeutic method capable of enhancing drug uptake efficacy in cells. Utilizing nsPEFs configured at 400 pulses, an electric field strength of 15 kV/cm, a pulse duration of 100 ns, and [...] Read more.

The combination of nanosecond Pulsed Electric Field (nsPEF) with pharmaceuticals is a pioneering therapeutic method capable of enhancing drug uptake efficacy in cells. Utilizing nsPEFs configured at 400 pulses, an electric field strength of 15 kV/cm, a pulse duration of 100 ns, and a repetition rate of 10 pulses per second (PPS), we combined the nsPEF with a low dose of doxorubicin (DOX) at 0.5 μM. Upon verifying that cells could continuously internalize DOX from the surrounding medium within 1 h post nsPEF exposure, we set the DOX exposure period to 10 min and contrasted the outcomes of varying sequences of DOX and nsPEF administration: pulsing followed by DOX, DOX followed by pulsing, and DOX applied 40 min after pulsing. Flow cytometry, CCK-8 assays, and transmission electron microscopy (TEM) were employed to examine intracellular DOX accumulation, cell viability, apoptosis, cell cycle, and ultrastructural transformations. Our findings demonstrate that exposing cells to DOX 40 min subsequent to nsPEF treatment can effectively elevate intracellular DOX levels, decrease cell viability, and inhibit the cell cycle. This research work presents a novel approach to enhance DOX uptake efficiency with moderate conditions of both DOX and nsPEF. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

attachment

Supplementary material:
Supplementary File 1 (ZIP, 6566 KiB)

10 pages, 1405 KiB  

Open AccessReview

Non-Analog Compounds to Sialic Acid as Inhibitors of Influenza Virus Neuraminidase: An Underexplored Approach for Novel Antivirals―Systematic Review

by Luis Márquez-Domínguez, Carolina Jasso-Miranda, Virginia Sedeño-Monge and Gerardo Santos-López

Sci. Pharm. 2024, 92(2), 33; https://doi.org/10.3390/scipharm92020033 - 19 Jun 2024

Viewed by 588

Abstract

Influenza poses a significant threat to public health worldwide, particularly among vulnerable populations such as children, the elderly, immunocompromised individuals, and those with chronic diseases. It is associated with high mortality and morbidity rates. Neuraminidase inhibitors play a crucial role in influenza treatment [...] Read more.

Influenza poses a significant threat to public health worldwide, particularly among vulnerable populations such as children, the elderly, immunocompromised individuals, and those with chronic diseases. It is associated with high mortality and morbidity rates. Neuraminidase inhibitors play a crucial role in influenza treatment by mitigating the risk of complications and death. However, the genetic variability of the influenza virus enables the emergence of drug-resistant mutations. This review focuses on the search for new compounds that are not analogous to sialic acid, aiming to inhibit the activity of viral neuraminidase in vitro, viral replication in cell cultures, or animal models. Influenza virus strains that have been reported in the literature present specific mutations that generate resistance to neuraminidase inhibitors. Since these inhibitors bear structural resemblance to sialic acid, the predominant location for these mutations is the enzyme’s active site. Consequently, exploring alternative compound classes becomes imperative to circumvent this interaction pattern. These compounds will introduce diverse molecular frameworks, serving as foundational structures for further development through rational drug design, thereby engendering novel antiviral agents targeting influenza. The potential prospects for developing novel influenza antivirals based on these findings are discussed. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

►▼ Show Figures

Figure 1

14 pages, 12746 KiB  

Open AccessArticle

Adenosine Encapsulation and Characterization through Layer-by-Layer Assembly of Hydroxypropyl-β-Cyclodextrin and Whey Protein Isolate as Wall Materials

by Yudie Jin and Suning Zhang

Molecules 2024, 29(9), 2046; https://doi.org/10.3390/molecules29092046 - 29 Apr 2024

Cited by 1 | Viewed by 768

Abstract

Adenosine, as a water-soluble active substance, has various pharmacological effects. This study proposes a layer-by-layer assembly method of composite wall materials, using hydroxypropyl-$\beta$-cyclodextrin as the inner wall and whey protein isolate as the outer wall, to encapsulate adenosine within the core [...] Read more.

Adenosine, as a water-soluble active substance, has various pharmacological effects. This study proposes a layer-by-layer assembly method of composite wall materials, using hydroxypropyl-$\beta$-cyclodextrin as the inner wall and whey protein isolate as the outer wall, to encapsulate adenosine within the core material, aiming to enhance adenosine microcapsules’ stability through intermolecular interactions. By combining isothermal titration calorimetry with molecular modeling analysis, it was determined that the core material and the inner wall and the inner wall and the outer wall interact through intermolecular forces. Adenosine and hydroxypropyl-$\beta$-cyclodextrin form an optimal 1:1 complex through hydrophobic interactions, while hydroxypropyl-$\beta$-cyclodextrin and whey protein isolate interact through hydrogen bonds. The embedding rate of AD/Hp-$\beta$-CD/WPI microcapsules was 36.80%, and the 24 h retention rate under the release behavior test was 76.09%. The method of preparing adenosine microcapsules using composite wall materials is environmentally friendly and shows broad application prospects in storage and delivery systems with sustained release properties. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-3